Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The window of opportunity for treatment of progressive multiple sclerosis

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Implementation of the Stroke Action Plan for Europe 2018--2030 during coronavirus disease-2019

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Editorial: Remaining diagnostic issues and start of a treatment era for muscle diseases

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  3. The changing course of multiple sclerosis: rising incidence, change in geographic distribution, disease course, and prognosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The influence of lifestyle and gender on cluster headache

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Exercise in muscle disorders: what is our current state?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

PURPOSE OF REVIEW: Based on the knowledge of disease mechanisms in the progressive course of multiple sclerosis and the experience from randomized clinical trials, we assessed the timing of disease-modifying therapy in patients with progressive multiple sclerosis to define the optimal window of opportunity for treatment of progressive multiple sclerosis.

RECENT FINDINGS: In progressive multiple sclerosis both small molecules that cross the blood--brain barrier (siponimod) and monoclonal antibodies (ocrelizumab) have shown therapeutic efficacy and have been approved for treatment of progressive multiple sclerosis. However, the majority of phase II and phase III trials in progressive forms of multiple sclerosis have been negative, probably owing to either late start of treatment or use of drugs that are ineffective for treatment of progressive multiple sclerosis.

SUMMARY: Results from phase II and III trials suggest that the window of opportunity for treatment of progressive multiple sclerosis with anti-inflammatory drugs is predominantly in the early phase of the progressive disease course when patients have lower age, shorter duration of progressive multiple sclerosis, and more pronounced clinical and MRI inflammatory activity. Ongoing trials of neuroprotective drugs may widen the window of opportunity by expanding targeted pathophysiologies.

OriginalsprogEngelsk
TidsskriftCurrent Opinion in Neurology
Vol/bind33
Udgave nummer3
Sider (fra-til)262-270
Antal sider9
ISSN1350-7540
DOI
StatusUdgivet - jun. 2020

ID: 61640759